These findings are in accordance with the results of our recent study7 at the RNA level, where we showed, in both adult TCGA AML and the pediatric TARGET AML cohorts treated with ara-C, that SAMHD1 mRNA levels are not lower in patients achieving CR as compared to patients that do not achieve CR. The gene discussed is SAMHD1; the disease is acute myeloid leukemia.